gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · XGNHealthcareMedical Labs

Exagen Inc. Common Stock (XGN)

$8.51+2.04%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$8.37▼ 29.29% in range
Nov 3, 2025Low $2.65 · High $11.83Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Exagen closed at $8.51 on Nov 4, up 2.04%, 28.1% below its 52-week closing high. Volume of 132.7K shares was 0.38× its 20-day average (below normal).

Split-adjusted performance: +3.9% over one month, +175.4% over six months, -28.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $19.94M, up 15.9% from a year earlier, with a net margin of -16.0%.

Short interest was 673.9K shares at the Oct 15 settlement, down 4.4% from the prior report (3.9% of float, 1.8 days to cover).

Market cap$206.2M24.2M shares
Revenue · quarter$19.9M+15.9% YoY
Diluted EPS$-0.13—
P/E · TTM—P/S 2.9×
Net margin-16.0%Gross 61.3%
Dividend yieldNone
52-week range2.65 – 11.83−28.1% from high
Volume132.7K0.38× 20-day avg
Volatility · 60d56.4%Annualised
Short % of float3.9%1.8 days to cover
Net cash-$959.0KCash $24.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.3%1M +3.9%3M +29.1%6M +175.4%YTD +40.0%1Y −28.1%3Y +427.9%5Y −27.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum96
Revenue growth33
Net margin38
Value (low P/E)—
Size22

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short673.9K−4.4% vs prior
Days to cover1.8Settled Oct 15
% of float3.9%
Short vol. 10d47.0%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
XGNExagen$8.51+2.04%+175.4%+15.9%−16.0%—$206.2M
BDSXBiodesix$21.49+2.09%+43.3%+34.2%−27.1%—$226.7MCompare
SERASera Prognostics$2.02+4.40%+11.3%+76.5%−30463.3%—$79.5MCompare
FLGTFulgent Genetics$19.68+1.60%+31.9%+4.4%−34.6%—$541.5MCompare
CSTLCastle Biosciences$35.75+1.74%+44.4%+20.1%−2.0%—$1.09BCompare
FRNMFreenome$11.30−1.48%————$1.21BCompare
LMRILumexa Imaging Holdings$13.10+16.76%+27.4%—1.0%—$1.26BCompare
PSNLPersonalis$15.79+0.25%+160.1%+30.0%−141.7%—$1.69BCompare
FTREFortrea Holdings$20.83−0.57%+33.2%−1.4%0.1%—$2.01BCompare

News about Exagen

All news →
Exagen Inc. to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · 6d ago▲ Positive

Quick answers

What does Exagen do?
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
What is XGN's market cap?
$206.16M, based on the Nov 4 close of $8.51.
Does Exagen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of XGN is sold short?
673.9K shares, 3.9% of float, as of Oct 15, 2026.
What sector is XGN in?
Healthcare, in the Medical Labs industry.

About Exagen

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

HQ: Vista, CA220 employeesListed Sep 19, 2019exagen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology